By Fineline Cube 
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical‑device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD 533 million, in addition to the equity already held by Boston Scientific since 2017.
Strategic Rationale
- Deepening Pain‑Management Offerings – Nalu’s FDA‑approved Nalu Neurostimulation System delivers targeted peripheral nerve stimulation (PNS) for adults with intractable, severe chronic peripheral neuropathic pain (e.g., shoulder, lower back, and knee pain).
- Technology Synergy – The system’s tiny, battery‑free implantable pulse generator is wirelessly powered by a small external therapy disc and controlled via a smartphone app, aligning with Boston Scientific’s focus on connected, minimally invasive devices.
- Market Opportunity – Chronic pain affects over 50 million adults in the U.S. alone; the acquisition positions Boston Scientific to capture a growing segment of the rapidly expanding neuromodulation market.
Key Transaction Details
| Item | Description |
|---|---|
| Acquisition Price | USD 533 million (upfront) + existing equity stake |
| Previous Investment | Boston Scientific has been a strategic investor in Nalu since 2017 |
| Regulatory Status | Nalu Neurostimulation System received FDA approval in 2019 |
| Technology Overview | • Peripheral nerve stimulation via mild electrical pulses • Wireless, battery‑free implantable pulse generator • External therapy disc + smartphone‑controlled app |
Nalu Neurostimulation System Highlights
- Targeted Pain Modulation – Delivers precise electrical pulses to peripheral nerves, blocking pain signals before they reach the brain.
- Minimally Invasive – Small implant size and battery‑free design reduce surgical complexity and improve patient compliance.
- Remote Management – Smartphone app enables clinicians to adjust therapy settings and monitor patient progress in real time.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech